Search Results for: ALK

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
HMGB1 high mobility group box 1
  • ER-Phagosome pathway
  • Apoptosis induced DNA fragmentation
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • TAK1-dependent IKK and NF-kappa-B activation
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • Pyroptosis
  • Regulation of TLR by endogenous ligand
  • Neutrophil degranulation
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • TRAF6 mediated NF-kB activation
  • Chloroquine
  • Ethyl pyruvate
IKBKG inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • SUMOylation of immune response proteins
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Regulation of NF-kappa B signaling
  • PKR-mediated signaling
  • SLC15A4:TASL-dependent IRF5 activation
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Modulation of host responses by IFN-stimulated genes
  • AGRO100
  • Tarenflurbil
  • Incontinentia pigmenti
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
IRS1 insulin receptor substrate 1
  • PI3K Cascade
  • IRS-mediated signalling
  • SOS-mediated signalling
  • SOS-mediated signalling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • PI3K/AKT activation
  • PI3K/AKT activation
  • Signaling by ALK
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • IRS-related events triggered by IGF1R
  • Signaling by Leptin
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Activated NTRK3 signals through PI3K
  • Signaling by ALK fusions and activated point mutants
  • Growth hormone receptor signaling
  • Signaling by LTK
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
JAK3 Janus kinase 3
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by ALK
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • R-348
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Abrocitinib
  • Zanubrutinib
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
MDK midkine
  • Signaling by ALK
  • Signaling by ALK
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • MDK and PTN in ALK signaling
  • MDK and PTN in ALK signaling
MSH2 mutS homolog 2
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Defective Mismatch Repair Associated With MSH3
  • Defective Mismatch Repair Associated With MSH2
  • Defective Mismatch Repair Associated With MSH6
  • TP53 Regulates Transcription of DNA Repair Genes
  • Ovarian cancer
  • Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
  • Colorectal cancer
NLRC4 NLR family CARD domain containing 4
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • The IPAF inflammasome
  • The IPAF inflammasome
NPM1 nucleophosmin 1
  • Nuclear import of Rev protein
  • Nuclear import of Rev protein
  • SUMOylation of transcription cofactors
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation
  • SARS-CoV-1-host interactions
  • ALK mutants bind TKIs
  • Signaling by ALK fusions and activated point mutants
  • Nuclear events stimulated by ALK signaling in cancer
  • PKR-mediated signaling
  • Artenimol
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Signaling by ALK
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • RHOF GTPase cycle
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Signaling by LTK in cancer
  • Signaling by LTK
  • Co-stimulation by ICOS
  • SF1126
  • Enzastaurin
  • Wortmannin
PLCG1 phospholipase C gamma 1
  • ISG15 antiviral mechanism
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • PLC-gamma1 signalling
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream signal transduction
  • Signaling by ALK
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • Role of phospholipids in phagocytosis
  • PECAM1 interactions
  • EGFR interacts with phospholipase C-gamma
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Role of second messengers in netrin-1 signaling
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated cell proliferation
  • Constitutive Signaling by EGFRvIII
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RET signaling
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PLCG1
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through PLCG1
  • FCGR3A-mediated IL10 synthesis
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by ALK fusions and activated point mutants
PPM1A protein phosphatase, Mg2+/Mn2+ dependent 1A
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Energy dependent regulation of mTOR by LKB1-AMPK
PTN pleiotrophin
  • Signaling by ALK
  • Signaling by ALK
  • MDK and PTN in ALK signaling
  • MDK and PTN in ALK signaling
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Co-inhibition by CTLA4
  • Co-inhibition by PD-1
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • FLT3 Signaling
  • STAT5 Activation
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Co-inhibition by BTLA
  • Dodecyltrimethylammonium
  • Metachondromatosis
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
PTPRZ1 protein tyrosine phosphatase receptor type Z1
  • Other interleukin signaling
  • MDK and PTN in ALK signaling
RASA1 RAS p21 protein activator 1
  • Downstream signal transduction
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • VEGFR2 mediated cell proliferation
  • Regulation of RAS by GAPs
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
SHC1 SHC adaptor protein 1
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signalling to RAS
  • SHC1 events in EGFR signaling
  • Tie2 Signaling
  • Integrin signaling
  • XBP1(S) activates chaperone genes
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
SHC3 SHC adaptor protein 3
  • Signalling to RAS
  • Signalling to RAS
  • RAF/MAP kinase cascade
  • RET signaling
SMC1A structural maintenance of chromosomes 1A
  • Meiotic synapsis
  • Separation of Sister Chromatids
  • Establishment of Sister Chromatid Cohesion
  • Cohesin Loading onto Chromatin
  • Resolution of Sister Chromatid Cohesion
  • SUMOylation of DNA damage response and repair proteins
  • Estrogen-dependent gene expression
  • Cornelia de Lange syndrome (CdLS)
TNFRSF8 TNF receptor superfamily member 8
  • TNFs bind their physiological receptors
  • Iratumumab
  • XmAb 2513
  • Brentuximab vedotin
TSPAN16 tetraspanin 16

Page 3 out of 4 pages